The Guidelines in Action - Treatment Dilemmas in Clinical Practice, Case 2: Juggling Antiretroviral Therapy and Cardiovascular Risk
2008-09-18 - English

Sexual Transmission of Hepatitis B and C
2008-09-17 - English

After viewing this presentation the participant will be able to discuss:
• The epidemiology of Hepatitis B and Hepatitis C
• Transmission risks of HBV and HCV, with an emphasis on sexual transmission
• Clinical manifestations of HBV and HCV
• Prevention of virus transmission
• Post-exposure prophylaxis for HBV

Sex, Drugs and Disease Transmission
2008-09-17 - English

After viewing this presentation the participant will be able to discuss:
• The link between methamphetamine use and risky sexual behavior
• The clinical impact of methamphetamine in people with HIV infection.
• Treatment for methamphetamine dependence
• The link between Viagra use and risky sexual behavior

Acute HIV and STDs: Screening and Co-infection
2008-09-17 - English

After viewing this presentation the participant will be able to discuss:
• detection methods for acute HIV infection (AHI)
• common STI co-infections with HIV
• the impact of STI co-infections on the detection of AHI

HIV, Cancer, and Immune Deficiency
2008-09-18 - English

After viewing this presentation, the participant will be able to discuss:
• The relationship between infection-related cancers and HIV infection
• Levels of immune deficiency and corresponding cancer risks.
• The possibility of reversing cancer risks with improved immune function.

HIV Infection and Healthy Ageing: Is There a Need For HIV-Specific Management Guidelines for the Protection of Hearts, Bones, Minds and More?
2008-09-18 - English

After viewing this presentation, the participant will be able to discuss:

• The relationship between HIV infection and cardiovascular risk
• Management of cardiovascular risk in patients with HIV
• The relationship between HIV infection and bone disease risk
• IAS guidelines other than CD4 count for initiation of antiretroviral therapy

How to Use the Newer Agents in the Treatment-Experienced Patient and What Drugs Are in the Pipeline
2008-09-18 - English

After viewing this presentation, the participant will be able to discuss:
• The newer agents and how to use them
• The drugs that might be available in the near future

The Guidelines in Action - Treatment Dilemmas in Clinical Practice, Case 1: Managing Suspected Early Virologic Failure
2008-09-18 - English

Biological Factors of Sexual Transmission of HIV
2008-09-19 - English

After viewing this presentation, the participant will be able to discuss:

• Viral loads in genital specimens of people with HIV
• The infectivity of people with HIV in relation to disease progression.
• The influence of STD co -infection on the transmission of HIV.

Initiation of Combination Antiretroviral Therapy in Adults with HIV-1-infection, What CD4 Threshold to Use - Overview of Clinical Trial Data 2008
2008-09-19 - English

After viewing this presentation the participant will be able to discuss:

• Current guidelines regarding the CD4+ threshold at which to initiate ART
• Rationale for increasing the CD4+ threshold for ART initiation in those guidelines
• Reasons for ART deferral

Emerging Issues about Potency and Toxicity of the Preferred Agents for Initial Therapy
2008-09-19 - English

After viewing this presentation the participant will be able to discuss:
• The preferred antiretroviral therapy agents according to the US DHHS Guidelines and the Australian guidelines.
• The emerging issues in 2008 concerning those agents.

Testing for latent TB in HIV Patients
2008-09-19 - English

(Presentation Module #1 - Alan Street )
After viewing this presentation, the participant will be able to discuss:

• Testing for latent tuberculosis in HIV patients with tuberculin skin test (TST) or interferon gamma release assay (IGRA)

(Presentation Module #2 -...(more)

Elevated Levels of Interleukin-6 and D-Dimer are Associated with an Increased Risk of Death in Patients with HIV
2008-09-19 - English

After viewing this presentation the participant will be able to discuss:
• Baseline markers and their relationship to mortality in HIV patients
• Changes in markers following randomisation in the SMART trial
• How changes in markers relate to disease outcome

Cardiovascular Disease (CVD) Risk in the STEAL Study Cohort
2008-09-19 - English

After viewing this presentation the participant will be able to discuss:
• Results of the STEAL study pertaining to the risk of cardiovascular disease in HIV patients

HIV/Hepatitis B Co-Infection
2008-09-20 - English

After viewing this presentation the participant will be able to discuss:
• How to treat HIV/Hepatitis B co-infections
• Hepatic flare
• Assessment and monitoring of HIV/Hepatitis B co-infections

Immunopathogenesis of Hepatic Flare in HIV-Hepatitis B Virus (HBV) Co-Infected Individuals Following Initiation of HBV-Active Antiretroviral Therapy
2008-09-20 - English

After viewing this presentation the participant will be able to discuss:
• The results of the Tenofovir in Co-infection (TICO) study on hepatic flare in HIV/Hepatitis B co-infected patients

Tenofovir Based HAART is Associated with High Rates of HBV DNA Suppression and HBEAG Seroconversion in Thai HIV-HBV Coinfected Patients
2008-09-20 - English

After viewing this presentation, the participant will be able to discuss:
• The effect of tenofovir-based HAART on HBV DNA Suppression and Hepatitis ‘e’ antigen (HBEAG) Seroconversion in Thai HIV/HBV co-infected patients.

GBV-C vs. HIV-1 Several GBV-C Proteins Inhibit Different HIV Replication Steps
2008-09-20 - English

After viewing this presentation, the participant will be able to discuss:
• The inhibition of HIV by GBV-C

HIV and TB Co-infection
2008-09-20 - English

After viewing this presentation, the participant will be able to discuss:
• HIV and tuberculosis (TB) co-infection in Cape Town, South Africa.

Restoration of Immune Responses to M.tuberculosis in Patients with HIV and M.tuberculosis Infection is a Double-Edged Sword
2008-09-20 - English

After viewing this presentation, the participant will be able to discuss:
• HIV and tuberculosis co-infection
• Paradoxical tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS)